Study of Vortioxetine (Lu AA21004) in Major Depressive Disorder in Asian Countries

This study has been completed.
Information provided by (Responsible Party):
H. Lundbeck A/S Identifier:
First received: March 28, 2012
Last updated: November 25, 2013
Last verified: November 2013

This study will be conducted with the aim of investigating the efficacy, safety and tolerability of 10 mg/day Vortioxetine in Asian patients compared to an approved active comparator (venlafaxine extended release 150 mg/day).

Condition Intervention Phase
Major Depressive Disorder
Drug: Vortioxetine (Lu AA21004)
Drug: Venlafaxine extended release
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Treatment
Official Title: Randomised, Double-blind, Parallel-group, Active-comparator (Venlafaxine Extended Release), Fixed-dose Study of [Vortioxetine] Lu AA21004 in Major Depressive Disorder in Asian Countries

Resource links provided by NLM:

Further study details as provided by H. Lundbeck A/S:

Primary Outcome Measures:
  • Change from baseline in MADRS total score after 8 weeks of treatment in patients with Major Depressive Disorder (MDD) [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    Montgomery and Asberg Depression Rating Scale (MADRS) is a ten-item rating scale designed to assess the severity of the symptoms in depressive illness and to be sensitive to treatment effects. Symptoms are rated on a 7-point scale from 0 (no symptom) to 6 (severe symptom). Definitions of severity are provided at two-point intervals. The total score of the ten items ranges from 0 to 60.

Secondary Outcome Measures:
  • Change in CGI-S score from baseline to Week 8 [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    Clinical Global Impression Scale - Severity of Illness (CGI-S) provides the clinician's impression of the patient's current state of mental illness. The clinician uses his or her clinical experience of this patient population to rate the severity of the patient's current mental illness on a 7-point scale ranging from 1 (normal - not at all ill) to 7 (among the most extremely ill patients).

  • Change in CGI-I score from baseline to Week 8 [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    The Clinical Global Impression - Global Improvement (CGI-I) provides the clinician's impression of the patient's improvement (or worsening). The clinician assesses the patient's condition relative to a baseline on a 7-point scale ranging from 1 (very much improved) to 7 (very much worse). In all cases, the assessment should be made independent of whether the rater believes the improvement is drug-related or not.

  • Change in HAM-A total score from baseline to Week 8 [ Time Frame: Baseline and Week 8 ] [ Designated as safety issue: No ]
    Hamilton Anxiety Rating Scale (HAM-A) is a 14-item rating scale designed to assess the global anxiety. Each symptom is rated from 0 (absent) to 4 (maximum severity). The total score of the 14 items ranges from 0 to 56.

  • MADRS response at Week 8 (response defined as a ≥50% decrease in the MADRS total score from baseline) [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  • Remission at Week 8 (remission defined as a MADRS total score ≤10) [ Time Frame: Week 8 ] [ Designated as safety issue: No ]
  • Safety and tolerability of Vortioxetine [ Time Frame: Baseline to Week 8 ] [ Designated as safety issue: Yes ]
    Adverse event monitoring

Enrollment: 437
Study Start Date: May 2012
Primary Completion Date: October 2013 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Vortioxetine (Lu AA21004) Drug: Vortioxetine (Lu AA21004)
10 mg/day
Other Name: Brintellix
Active Comparator: Venlafaxine extended release Drug: Venlafaxine extended release
150 mg/day
Other Name: Efexor® XL


Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The patient suffers from recurrent MDD as the primary diagnosis according to DSM-IVTR™ criteria. The current Major Depressive Episode (MDE) should be confirmed using the Mini International Neuropsychiatric Interview (MINI)
  • The patient has a MADRS total score ≥26
  • The patient has a CGI-S score ≥4
  • The reported duration of the current MDE is ≥3 months.

Other inclusion criteria may apply.

Exclusion Criteria:

  • The patient meets any of the exclusion criteria listed in the protocol or, in the investigator's opinion, is unlikely to comply with the protocol or is unsuitable for any reason.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT01571453

Sponsors and Collaborators
H. Lundbeck A/S
Study Director: Email contact via H. Lundbeck A/S
  More Information

No publications provided

Responsible Party: H. Lundbeck A/S Identifier: NCT01571453     History of Changes
Other Study ID Numbers: 13926A
Study First Received: March 28, 2012
Last Updated: November 25, 2013
Health Authority: Korea: Food and Drug Administration
Taiwan : Food and Drug Administration

Keywords provided by H. Lundbeck A/S:

Additional relevant MeSH terms:
Depressive Disorder
Depressive Disorder, Major
Pathologic Processes
Mood Disorders
Mental Disorders
Behavioral Symptoms
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Anti-Anxiety Agents
Tranquilizing Agents
Central Nervous System Depressants
Serotonin 5-HT1 Receptor Agonists
Serotonin Receptor Agonists
Serotonin 5-HT1 Receptor Antagonists
Serotonin Antagonists
Serotonin 5-HT3 Receptor Antagonists processed this record on September 18, 2014